Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

被引：4

作者：

Garcia-Manero, Guillermo ^{[1
]}

Platzbecker, Uwe ^{[2
]}

Santini, Valeria ^{[3
]}

Zeidan, Amer M. ^{[4
,5
]}

Fenaux, Pierre ^{[6
]}

Komrokji, Rami S. ^{[7
]}

Shortt, Jake ^{[8
,9
]}

Valcarcel, David ^{[10
]}

Jonasova, Anna ^{[11
]}

Dimicoli-Salazar, Sophie ^{[12
]}

Tiong, Ing Soo ^{[13
]}

Lin, Chien-Chin ^{[14
]}

Li, Jiahui ^{[15
]}

Zhang, Jennie ^{[15
]}

Giuseppi, Ana Carolina ^{[15
]}

Kreitz, Sandra ^{[16
]}

Pozharskaya, Veronika ^{[15
]}

Keeperman, Karen L. ^{[15
]}

Rose, Shelonitda ^{[15
]}

Prebet, Thomas ^{[15
]}

Degulys, Andrius ^{[17
,18
]}

Paolini, Stefania ^{[19
]}

Cluzeau, Thomas ^{[20
]}

Della Porta, Matteo Giovanni ^{[21
,22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Univ Leipzig, Med Ctr, Dept Hematol Cellular Therapy Hemostaseol & Infec, Leipzig, Germany

[3] Univ Florence, Azienda Osped Univ Careggi, MDS Unit, DMSC, Florence, Italy

[4] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA

[5] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[6] Univ Paris 07, Hop St Louis, Paris, France

[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[8] Monash Univ, Melbourne, Australia

[9] Monash Hlth, Melbourne, Australia

[10] Hosp Univ Vall dHebron, Barcelona, Spain

[11] Charles Univ Prague, Gen Univ Hosp, Med Dept Hematol, Prague, Czech Republic

[12] Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France

[13] The Alfred, Malignant Haematol & Stem Cell Transplantat, Melbourne, Australia

[14] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Bristol Myers Squibb, Celgene Int Sarl, Boudry, Switzerland

[17] Vilnius Univ Hosp, Santaros Klinikos, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania

[18] Vilnius Univ, Fac Med, Inst Clin Med, Vilnius, Lithuania

[19] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[20] Univ Cote Azur, Dept Hematol Clin, CHU Nice, Nice, France

[21] Canc Ctr IRCCS Humanitas Res Hosp, Milan, Italy

[22] Humanitas Univ, Dept Biomed Sci, Milan, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178596

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 48 条

[41] The COMMANDS Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 18 - 20
[42] Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Santini, Valeria
Komrokji, Rami S.
Sekeres, Mikkael A.
Savona, Michael Robert
Fenaux, Pierre
Madanat, Yazan F.
Oliva, Esther
Buckstein, Rena
Jonasova, Anna
Germing, Ulrich
Mittelman, Moshe
Thepot, Sylvain
Riggs, Jennifer
Dougherty, Souria
Berry, Tymara
Navada, Shyamala
Xia, Qi
Sun, Libo
Zeidan, Amer M.
Platzbecker, Uwe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S386 - S387
[43] Imetelstat Treatment Leads to Durable Transfusion Independence in RBC Transfusion-Dependent, Non-Del(5q) Lower-Risk MDS Relapsed/Refractory to a Erythropoiesis-Stimulating Agent Who Are Lenalidomide- and HMA-Naive
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 12 - 13
[44] Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab with Darbepoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
Sallman, David A.
Hunter, Anthony M.
Xie, Zhuoer
McLemore, Amy
Kuykendall, Andrew T.
Nardelli, Lisa Ann
Chan, Onyee
Padron, Eric
Lancet, Jeffrey
Komrokji, Rami S.
BLOOD, 2023, 142
[45] Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)
Platzbecker, Uwe
Komrokji, Rami S.
Zeidan, Amer M.
Fenaux, Pierre
Sekeres, Mikkael A.
Savona, Michael R.
Madanat, Yazan F.
Jonasova, Anna
Illmer, Thomas
Sherman, Laurie
Berry, Tymara
Riggs, Jennifer
Xia, Qi
Navada, Shyamala
Wan, Ying
Huang, Fei
Feller, Faye M.
Santini, Valeria
BLOOD, 2023, 142
[46] RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
Garcia-Manero, G.
Bachiashvili, K.
Griffiths, E.
Traer, E.
Saini, L.
Amin, H.
Zeidan, A.
Mohan, S.
Lubbert, M.
Maness, L.
Foran, J.
Selleslag, D.
Xicoy, B.
Pollyea, D.
Sallman, D.
Al-Kali, A.
Berdeja, J.
Al-Ali, H.
Zhu, N.
Lopez, P. Font
Sanz, G.
Santini, V.
Yimer, H.
Cripe, L.
Priego, V.
Odenike, O.
Heyrman, B.
Valcarcel, D.
Vachhani, P.
Sano, Y.
Mirakhur, B.
Oganesian, A.
Keer, H.
Yacoub, A.
LEUKEMIA RESEARCH, 2023, 128
[47] Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
Garcia-Manero, Guillermo
Bachiashvili, Kimo
Griffiths, Elizabeth A.
Zeidan, Amer M.
Traer, Elie
Saini, Lalit
Amin, Harshad
Mohan, Sanjay
Lubbert, Michael
Maness-Harris, Lori
Foran, James
Selleslag, Dominik
Xicoy, Blanca
Pollyea, Daniel A.
Sallman, David A.
Al-Kali, Aref
Berdeja, Jesus G.
Al-Ali, Haifa
Zhu, Nancy Y.
Lopez, Patricia Font
Santillana, Guillermo Sanz
Santini, Valeria
Yimer, Habte
Cripe, Larry D.
Priego, Victor
Odenike, Olatoyosi
Heyrman, Bert
Ferreiras, David Valcarcel
Vachhni, Pankit J.
Chan, Winny
Sano, Yuri
Mirakhur, Beloo
Oganesian, Aram
Keer, Harold
Yacoub, Abdulraheem
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S376 - S377
[48] Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
Santini, Valeria
Almeida, Antonio
Giagounidis, Aristoteles
Groepper, Stephanie
Jonasova, Anna
Vey, Norbert
Mufti, Ghulam J.
Buckstein, Rena
Mittelman, Moshe
Platzbecker, Uwe
Shpilberg, Ofer
Ram, Ron
del Canizo, Consuelo
Gattermann, Norbert
Ozawa, Keiya
Zhong, Jim
Seguy, Francis
Hoenekopp, Albert
Beach, C. L.
Fenaux, Pierre
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →